Daniela Baertschi
Overview
Explore the profile of Daniela Baertschi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
20
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hasler-Strub U, Mueller A, Li Q, Thuerlimann B, Ribi K, Gerber S, et al.
J Geriatr Oncol
. 2022 Sep;
14(1):101372.
PMID: 36127284
Introduction: Standard-dose eribulin mesylate (1.4 mg/m d1 + 8) achieves clinical benefit rates of 26%-52% in patients with metastatic breast cancer (mBC). <10% of patients in the registration trial were ...
2.
Salvatore L, Bria E, Sperduti I, Hinke A, Hegewisch-Becker S, Aparicio T, et al.
Cancer Treat Rev
. 2021 Apr;
97:102202.
PMID: 33838596
Background: The real impact of bevacizumab maintenance as single agent in metastatic colorectal cancer (mCRC) remains unclear. SAKK-41/06 and PRODIGE-9 failed to demonstrate the non-inferiority and superiority of bevacizumab versus...
3.
Kienle D, Dietrich D, Ribi K, Wicki A, Quagliata L, Winterhalder R, et al.
J Geriatr Oncol
. 2018 Dec;
10(2):304-310.
PMID: 30559073
Introduction: While the anti-VEGF antibody bevacizumab was studied repeatedly as part of low-intensity regimens in less fit elderly patients with metastatic colorectal cancer (mCRC), anti-EGFR antibodies as upfront treatment modality...
4.
Matter-Walstra K, Schwenkglenks M, Betticher D, Von Moos R, Dietrich D, Baertschi D, et al.
Clin Colorectal Cancer
. 2016 Apr;
15(4):314-320.e2.
PMID: 27117056
Background: Bevacizumab (BEV)-containing therapies are costly. We performed a health economic analysis of a randomized phase 3 study (SAKK 41/06) that compared BEV continuation as a single agent (BEV) with...